1.
Blauvelt A, Fowler, Jr. JF, Schuck E, Jauch J, Woehling H, Leonardi CL. A Randomized, Double-Blind, Multicenter Study to Compare the Efficacy, Safety, and Immunogenicity of a Proposed Adalimumab Biosimilar (GP2017) with Originator Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis. J of Skin [Internet]. 2017Oct.27 [cited 2022May18];1(3.1):s29. Available from: https://www.jofskin.org/index.php/skin/article/view/202